ArticleCanadian liver journal2025
Evaluation of a novel albumin platelet product (APP) fibrosis index and three non-invasive fibrosis indices in metabolic dysfunction-associated steatotic liver disease.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Albumin platelet product (APP) is a novel blood-based biomarker for liver fibrosis staging. This study evaluates APP's performance against Fibrosis-4 index (FIB-4), AST-platelet ratio index (APRI), and aspartate aminotransferase-alanine aminotransferase (AST/ALT) ratio in diagnosing advanced fibrosis and cirrhosis in metabolic dysfunction-associated steatotic liver disease (MASLD) patients with and without diabetes (DM). Method: Adults with MASLD/metabolic dysfunction-associated steatohepatitis (MASH) in 2010-2023 and available fibrosis staging biomarkers were included. Clinical fibrosis staging was confirmed by liver biopsy, transient elastography (FibroScan), and/or magnetic resonance elastography. Fibrosis staging-matched fibrosis biomarkers were calculated and analyzed. Results: A total of 570 patients (48.6% male) with available clinical staging and biomarkers were analyzed. DM was present in 38% of the cohort with a significantly higher prevalence among those with advanced fibrosis or cirrhosis ( Conclusion: APP outperformed FIB4 in detecting cirrhosis or advanced fibrosis among patients with DM and was comparable in non-DM patients. Revised FIB-4 thresholds may be needed in MASLD/MASH patients with DM to improve its diagnostic accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.